Beyond scientific rigor, designing a truly effective clinical trial protocol is a creative process. It involves artfully controlling for variables, selecting novel endpoints, and structuring the study to answer the core question in the most elegant and precise way possible, much like creating a piece of art.

Launching experiments without prior customer interviews or market analysis is a waste of resources. The most effective experiments are designed to answer specific questions that arise from a solid research foundation, not to substitute for it.

Many medtech companies design large trials where a tiny, clinically meaningless response can be statistically significant. Dr. Holman advises entrepreneurs to instead run rigorous trials that prove genuine clinical value, arguing that credible data is the ultimate moat, even if it carries a higher risk of failure.

Standard AI benchmarks are an engineering tool for measuring performance. A more scientific approach, borrowed from cognitive psychology, uses targeted experiments. By designing problems where specific patterns of success and failure are diagnostic, researchers can uncover the underlying mechanisms and principles of an AI system, yielding deeper insights than a simple score.

After an intervention like cash transfers has been validated by over 100 randomized trials, spending more money on another study is unethical. That funding is being taken from potential beneficiaries to measure something already known, preventing more lives from being improved.

The most valuable lessons in clinical trial design come from understanding what went wrong. By analyzing the protocols of failed studies, researchers can identify hidden biases, flawed methodologies, and uncontrolled variables, learning precisely what to avoid in their own work.

The traditional drug-centric trial model is failing. The next evolution is trials designed to validate the *decision-making process* itself, using platforms to assign the best therapy to heterogeneous patient groups, rather than testing one drug on a narrow population.

Reflecting on his PhD, Terry Rosen emphasizes that experiments that fail are often the most telling. Instead of discarding negative results, scientists should analyze them deeply. Understanding *why* something didn't work provides critical insights that are essential for iteration and eventual success.

The key public health failure during the pandemic was not initial uncertainty, but the systemic inability to execute rapid experiments. Basic, knowable questions about transmission, masks, and safe distances went unanswered because of a failure to generate data through randomized trials.